Masoud Parish1, Farnaz Valiyi1, Hadi Hamishehkar2, Sarvin Sanaie3, Mohammad Asghari Jafarabadi4, Samad Ej Golzari5, Ata Mahmoodpoor1. 1. Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Applied Drug Research Center, Department of Clinical Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Tuberculosis & Lung Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Road Traffic Injury Research Center, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
PURPOSE: The aim of this study was to evaluate the effect of an enteral nutrition diet, enriched with omega-3 fatty acids because of its anti-inflammatory effects on treatment of patients with mild to moderate ARDS. METHODS: This randomized clinical trial was performed in two ICUs of Tabriz University of Medical Sciences from Jun 2011 until Sep 2013 in north west of Iran. Fifty-eight patients with mild to moderate ARDS were enroled in this clinical trial. All patients received standard treatment for ARDS based on ARDS network trial. In intervention group, patients received 6 soft-gels of omega-3/day in addition to the standard treatment. RESULTS:Tidal volume, PEEP, pH, PaO2/FiO2 , SaO2, P platue and PaCO2 on the 7(th) and 14(th) days didn't have significant difference between two groups. Indices of lung mechanics (Resistance, Compliance) had significant difference between the groups on the 14(th) day. Pao2 had significant difference between two groups on both 7(th) and 14(th) days. Trend of PaO2 changes during the study period in two groups were significant. We showed that adjusted mortality rate did not have significant difference between two groups. CONCLUSION: It seems that adding omega-3 fatty acids to enteral diet of patients with ARDS has positive results in term of ventilator free days, oxygenation, lung mechanic indices; however, we need more multi center trials with large sample size and different doses of omega-3 fatty acids for their routine usage as an adjuant for ARDS treatment.
RCT Entities:
PURPOSE: The aim of this study was to evaluate the effect of an enteral nutrition diet, enriched with omega-3 fatty acids because of its anti-inflammatory effects on treatment of patients with mild to moderate ARDS. METHODS: This randomized clinical trial was performed in two ICUs of Tabriz University of Medical Sciences from Jun 2011 until Sep 2013 in north west of Iran. Fifty-eight patients with mild to moderate ARDS were enroled in this clinical trial. All patients received standard treatment for ARDS based on ARDS network trial. In intervention group, patients received 6 soft-gels of omega-3/day in addition to the standard treatment. RESULTS: Tidal volume, PEEP, pH, PaO2/FiO2 , SaO2, P platue and PaCO2 on the 7(th) and 14(th) days didn't have significant difference between two groups. Indices of lung mechanics (Resistance, Compliance) had significant difference between the groups on the 14(th) day. Pao2 had significant difference between two groups on both 7(th) and 14(th) days. Trend of PaO2 changes during the study period in two groups were significant. We showed that adjusted mortality rate did not have significant difference between two groups. CONCLUSION: It seems that adding omega-3 fatty acids to enteral diet of patients with ARDS has positive results in term of ventilator free days, oxygenation, lung mechanic indices; however, we need more multi center trials with large sample size and different doses of omega-3 fatty acids for their routine usage as an adjuant for ARDS treatment.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: Andrés Esteban; Antonio Anzueto; Fernando Frutos; Inmaculada Alía; Laurent Brochard; Thomas E Stewart; Salvador Benito; Scott K Epstein; Carlos Apezteguía; Peter Nightingale; Alejandro C Arroliga; Martin J Tobin Journal: JAMA Date: 2002-01-16 Impact factor: 56.272
Authors: Renee D Stapleton; Thomas R Martin; Noel S Weiss; Joseph J Crowley; Stephanie J Gundel; Avery B Nathens; Saadia R Akhtar; John T Ruzinski; Ellen Caldwell; J Randall Curtis; Daren K Heyland; Timothy R Watkins; Polly E Parsons; Julie M Martin; Mark M Wurfel; Teal S Hallstrand; Kathryn A Sims; Margaret J Neff Journal: Crit Care Med Date: 2011-07 Impact factor: 7.598
Authors: J E Gadek; S J DeMichele; M D Karlstad; E R Pacht; M Donahoe; T E Albertson; C Van Hoozen; A K Wennberg; J L Nelson; M Noursalehi Journal: Crit Care Med Date: 1999-08 Impact factor: 7.598
Authors: Todd W Rice; Arthur P Wheeler; B Taylor Thompson; Bennett P deBoisblanc; Jay Steingrub; Peter Rock Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: Teodoro Grau-Carmona; Vicente Morán-García; Abelardo García-de-Lorenzo; Gabriel Heras-de-la-Calle; Belén Quesada-Bellver; Jorge López-Martínez; Camilo González-Fernández; Juan C Montejo-González; Antonio Blesa-Malpica; Immaculada Albert-Bonamusa; Alfonso Bonet-Saris; José I Herrero-Meseguer; Alfonso Mesejo; Jose Acosta Journal: Clin Nutr Date: 2011-04-06 Impact factor: 7.324
Authors: Niall D Ferguson; Eddy Fan; Luigi Camporota; Massimo Antonelli; Antonio Anzueto; Richard Beale; Laurent Brochard; Roy Brower; Andrés Esteban; Luciano Gattinoni; Andrew Rhodes; Arthur S Slutsky; Jean-Louis Vincent; Gordon D Rubenfeld; B Taylor Thompson; V Marco Ranieri Journal: Intensive Care Med Date: 2012-08-25 Impact factor: 17.440
Authors: Vera M Barbosa; Elizabeth A Miles; Conceição Calhau; Estevão Lafuente; Philip C Calder Journal: Crit Care Date: 2010-01-19 Impact factor: 9.097
Authors: Ahilanandan Dushianthan; Rebecca Cusack; Victoria A Burgess; Michael Pw Grocott; Philip C Calder Journal: Cochrane Database Syst Rev Date: 2019-01-24